Publications by authors named "Goncalo Pinto Salgueiro"
Article Synopsis
- * The IL-17 pathway has been identified as a key player in HS inflammation, leading to the development of IL-17 inhibitors like secukinumab and bimekizumab, both of which have gained regulatory approvals for treating moderate-to-severe HS.
- * Ongoing clinical trials are exploring newer drugs like sonelokimab and izokibep, which show promise in treating HS, while this review summarizes the latest findings and advancements in understanding
